Joint Circle Pharmaceuticals (600513.SH) plans to sign a technology cooperation and development contract with Nanjing University to jointly research and develop anti-thrombotic small nucleic acid drugs.

Wisdom Finance APP News, Lianhuang Pharmaceutical (600513.SH) issued an announcement that the company intends to sign a "Technology Cooperation and Development Contract" with Nanjing University, with the contract targeting the joint research and development of anti-thrombotic nucleic acid drugs. The total amount of the contract is 15 million yuan (including tax), and according to the project development plan, the company will pay the cooperation fees to Nanjing University in installments as agreed in the contract. In addition, after the successful research and development of the target drug and its listing for sale, the company will need to pay a certain percentage of the annual revenue from the target drug to Nanjing University as royalties for a period of 10 years.